Testosterone treatment and risk of venous thromboembolism: population based case-control study
暂无分享,去创建一个
Samy Suissa | David J Handelsman | B. Freedman | C. Martinez | S. Suissa | David Handelsman | S. Rietbrock | A. Cohen | Alexander T Cohen | Ben Freedman | Carlos Martinez | Stephan Rietbrock | Anja Katholing | A. Katholing
[1] W. Spitzer,et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. , 1997, Contraception.
[2] A. Turpie,et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.
[3] Sonal Singh,et al. Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews. , 2016, The lancet. Diabetes & endocrinology.
[4] A. Araujo,et al. Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-Analysis , 2011 .
[5] K. Bhaskaran,et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.
[6] C. Martinez,et al. Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer , 2014, Thrombosis and Haemostasis.
[7] U. Winkler. Effects of androgens on haemostasis , 1996 .
[8] E. Løkkegaard,et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9 , 2011, BMJ : British Medical Journal.
[9] S. Suissa. The Quasi-cohort approach in pharmacoepidemiology: upgrading the nested case-control. , 2015, Epidemiology.
[10] J. Morley,et al. Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review , 2016, Clinical endocrinology.
[11] J. Shuster,et al. Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis , 2014, BMC Medicine.
[12] D. Muram,et al. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis. , 2013, The journal of sexual medicine.
[13] C. Glueck,et al. Thrombophilia in 67 Patients With Thrombotic Events After Starting Testosterone Therapy , 2016, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[14] David Handelsman. Global trends in testosterone prescribing, 2000–2011: expanding the spectrum of prescription drug misuse , 2013, The Medical journal of Australia.
[15] D. Berlowitz,et al. Ascertainment of Testosterone Prescribing Practices in the VA , 2015, Medical care.
[16] A. Jette,et al. Adverse events associated with testosterone administration. , 2010, The New England journal of medicine.
[17] J. Gore,et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study , 2009, Journal of Thrombosis and Thrombolysis.
[18] Effects of Testosterone Treatment in Older Men. , 2018, The New England journal of medicine.
[19] David Handelsman. Irrational Exuberance in Testosterone Prescribing: When Will the Bubble Burst? , 2015, Medical care.
[20] N. Smith,et al. Testosterone treatment and mortality in men with low testosterone levels. , 2012, The Journal of clinical endocrinology and metabolism.
[21] T. Perls,et al. Disease Mongering of Age‐Associated Declines in Testosterone and Growth Hormone Levels , 2015, Journal of the American Geriatrics Society.
[22] J. Kaufman,et al. Beneficial and adverse effects of testosterone on the cardiovascular system in men. , 2013, The Journal of clinical endocrinology and metabolism.
[23] David Handelsman. Androgen Physiology, Pharmacology and Abuse , 2013 .
[24] B. Dawn,et al. Association Between Testosterone Replacement Therapy and the Incidence of DVT and Pulmonary Embolism: A Retrospective Cohort Study of the Veterans Administration Database. , 2016, Chest.
[25] A. Isidori,et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis , 2014, Expert opinion on drug safety.
[26] S. Greenland,et al. Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men , 2014, PloS one.
[27] N. Goldenberg,et al. Thrombotic events after starting exogenous testosterone in men with previously undiagnosed familial thrombophilia. , 2011, Translational research : the journal of laboratory and clinical medicine.
[28] C. Schooling,et al. Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment: comment , 2015, Journal of thrombosis and haemostasis : JTH.
[29] S. Resnick,et al. Effects of Testosterone Treatment in Older Men. , 2016, The New England journal of medicine.
[30] E. Negri,et al. Venous thromboembolism in women: a specific reproductive health risk. , 2013, Human reproduction update.
[31] Y. Kuo,et al. Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy. , 2015, Mayo Clinic proceedings.
[32] U. Winkler,et al. Effects of androgens on haemostasis. , 1996, Maturitas.
[33] G. Grunwald,et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. , 2013, JAMA.
[34] B. Cowling,et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials , 2013, BMC Medicine.
[35] David Handelsman,et al. Complications of injectable testosterone undecanoate in routine clinical practice. , 2015, European journal of endocrinology.
[36] G M Leydon,et al. Validation of the diagnosis of venous thromboembolism in general practice database studies. , 2000, British journal of clinical pharmacology.
[37] K. Heinemann,et al. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. , 2014, Contraception.
[38] L. Heinemann,et al. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. , 2007, Contraception.
[39] O. Miettinen,et al. Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions. , 1989, Journal of clinical epidemiology.